```
=> d his

     (FILE 'HOME' ENTERED AT 12:03:38 ON 29 DEC 2009)

     FILE 'REGISTRY' ENTERED AT 12:03:50 ON 29 DEC 2009
L1          2111 S C4S-C6N/EA
L2         13444 S C3N2-C6N/EA
L3          3493 S C5N-C6N/EA
L4               STRUCTURE UPLOADED
L5         19048 S L1 OR L2 OR L3
L6            37 S L4  SUB=L5 SAM
L7           815 S L4  SUB=L5 FUL
L8             4 S L1 AND L7
L9           270 S L2 AND L7
L10          541 S L3 AND L7

     FILE 'CAPLUS' ENTERED AT 12:16:02 ON 29 DEC 2009
L11            3 S L8
L12            5 S L9
L13           57 S L10

     FILE 'REGISTRY' ENTERED AT 12:16:23 ON 29 DEC 2009
L14              STRUCTURE UPLOADED
L15           68 S L14  SUB=L7 FUL
L16           64 S L15 AND CAPLUS/LC
L17            4 S L15 NOT L16

     FILE 'CAPLUS' ENTERED AT 12:39:37 ON 29 DEC 2009
L18            7 S L15

=> d ibib abs hitstr total
```

L18 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:1124035 CAPLUS
DOCUMENT NUMBER: 145:455007
TITLE: Preparation of oxadiazaazuleneamines as cannabinoid receptor ligands.
INVENTOR(S): Carpino, Philip Albert; Dow, Robert Lee
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 74pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006111849	A1	20061026	WO 2006-IB1021	20060410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2605479	A1	20061026	CA 2006-2605479	20060410
EP 1874779	A1	20080109	EP 2006-744571	20060410
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008536909	T	20080911	JP 2008-507192	20060410
NL 1031627	A1	20061023	NL 2006-1031627	20060419
NL 1031627	C2	20070710		
US 20060241100	A1	20061026	US 2006-409458	20060420
PRIORITY APPLN. INFO.:			US 2005-673546P P	20050420
			WO 2006-IB1021 W	20060410

OTHER SOURCE(S): CASREACT 145:455007; MARPAT 145:455007
GI



I

AB Title compds. [I; R1, R2 = (substituted) aryl, heteroaryl; V = O, W = CR31R32, or V = CR31R32, W = NR4; R31, R32, R51, R52, R61, R62, R71 = H, alkyl, haloalkyl; R4 = H, alkyl, haloalkyl, alkoxycarbonyl, aryl, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl; R72 = H, alkyl, alkenyl, haloalkyl, etc.], were prepared Thus, I (R1 = 2-ClC6H4; R2 = 4-ClC6H4; R51, R52, R61, R62, R71 = H; R72 = Me; V = O; W = CH2) (preparation outlined) showed cannabinoid CB1 receptor binding activity of 47 nM.

IT 913369-13-8P 913369-14-9P 913369-15-0P
913369-16-1P 913369-17-2P 913369-18-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxadiazaazuleneamines as cannabinoid receptor ligands)

RN 913369-13-8 CAPLUS

CN Pyrazolo[4,3-c]azepine-5(4H)-carboxylic acid, 8-amino-2-(2-chlorophenyl)-2,6,7,8-tetrahydro-3-[4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 913369-14-9 CAPLUS

CN Propanamide, N-[2-(2-chlorophenyl)-2,4,5,6,7,8-hexahydro-3-[4-(trifluoromethyl)phenyl]pyrazolo[4,3-c]azepin-8-yl]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 913369-15-0 CAPLUS
CN Propanamide, N-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2,4,5,6,7,8-hexahydropyrazolo[4,3-c]azepin-8-yl]-2-methyl- (CA INDEX NAME)



RN 913369-16-1 CAPLUS
CN Urea, N'-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2,4,5,6,7,8-hexahydropyrazolo[4,3-c]azepin-8-yl]-N,N-diethyl- (CA INDEX NAME)



RN 913369-17-2 CAPLUS
CN Carbamic acid, [2-(2-chlorophenyl)-3-(4-chlorophenyl)-2,4,5,6,7,8-hexahydropyrazolo[4,3-c]azepin-8-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 913369-18-3 CAPLUS
CN Propanamide, N-[2-(2-chlorophenyl)-2,4,5,6,7,8-hexahydro-3-[4-(trifluoromethyl)phenyl]pyrazolo[4,3-c]azepin-8-yl]-2-methyl- (CA INDEX NAME)



IT 1148140-81-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of oxadiazaazuleneamines as cannabinoid receptor ligands)
RN 1148140-81-1 CAPLUS
CN Pyrazolo[4,3-c]azepine-5(4H)-carboxylic acid, 8-amino-2-(2-chlorophenyl)-3-(4-chlorophenyl)-2,6,7,8-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1130645 CAPLUS
DOCUMENT NUMBER: 143:386939
TITLE: Preparation of heterocyclic azepine derivatives as inhibitor of cholesterol ester transfer protein
INVENTOR(S): Bell, Michael Gregory; Cao, Guoqing; Escribano, Ana Maria; Fernandez, Maria Carmen; Mantlo, Nathan Bryan; Martin de la Nava, Eva Maria; Mateo Herranz, Ana Isabel; Mayhugh, Daniel Ray; Wang, Xiaodong
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005097805	A1	20051020	WO 2005-US9294		20050317
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1732933	A1	20061220	EP 2005-732643		20050317
EP 1732933	B1	20080723			
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
AT 402180	T	20080815	AT 2005-732643		20050317
PT 1732933	E	20081020	PT 2005-732643		20050317
ES 2308477	T3	20081201	ES 2005-732643		20050317
ES 2326326	T3	20091007	ES 2005-725968		20050317
ZA 2006006737	A	20080227	ZA 2006-6737		20060814
US 20070208003	A1	20070906	US 2006-598686		20060908
PRIORITY APPLN. INFO.:			US 2004-557134P	P	20040326
			US 2004-621162P	P	20041022
			WO 2005-US9294	W	20050317

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:386939; MARPAT 143:386939
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Q = (CH2)j; n = 0-3; m = 0-6; j = 1-2; q = 0-2; W, X, Y and Z independently = CH, C, N, etc.; A = 5-6 membered ring wherein one of W, X, Y or Z may be absent with provisions; K = bond, CO or S(O)p; p = 0-2; R1 = OH, alkyl, alkenyl, etc.; R2 = H, halo, alkynyl, etc.; R3 = H,

aryl, cycloalkyl, etc.; R4 = NR7R8; R5 = H, OH, halo, etc.; R6 = H, alkyl, alkenyl, etc.; R7 = alkyl, alkenyl, cycloalkyl, etc.; R8 = aryl, alkylaryl, alkenylaryl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of cholesterol ester transfer protein (CEPT). Thus, e.g., II was prepared by cyclization of 4-[isopropoxycarbonyl-(3-methoxycarbonyl-propyl)-amino]-thiophene-3-carboxylic acid Me ester (preparation given) using potassium tert-butoxide followed by decarboxylation/amination sequence using 3,5-bis(trifluoromethyl)benzylamine and subsequent acylation using acetic anhydride. The ability of I to inhibit the transfer of radiolabeled cholesterol esters between HDL and LDL was evaluated using an in vitro scintillation proximity assay and it was revealed that compds. of the invention possessed an activity of below 100 μM. I should prove useful in the treatment of dyslipidemia. Pharmaceutical compns. comprising I are disclosed.

IT 866774-51-8P 866774-57-4P 866774-59-6P
866774-61-0P 866774-63-2P 866774-65-4P
866774-67-6P 866774-69-8P 866774-70-1P
866774-71-2P 866774-72-3P 866774-73-4P
866774-74-5P 866774-76-7P 866774-77-8P
866774-78-9P 866774-79-0P 866774-80-3P
866774-81-4P 866774-82-5P 866774-83-6P
866774-84-7P 866774-85-8P 866774-86-9P
866774-87-0P 866774-88-1P 866774-89-2P
866774-90-5P 866774-91-6P 866774-92-7P
866774-93-8P 866774-94-9P 866774-95-0P
866774-96-1P 866774-97-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic azepine derivs. as inhibitors of cholesterol ester transfer protein)

RN 866774-51-8 CAPLUS

CN 1H-Thieno[3,4-b]azepine-1-carboxylic acid, 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-57-4 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-chloro-6,7,8,9-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-59-6 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6,7,8,9-tetrahydro-2-methoxy-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-61-0 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-bromo-6,7,8,9-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-63-2 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-(dimethylamino)-6,7,8,9-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-65-4 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6,7,8,9-tetrahydro-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-67-6 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-cyano-6,7,8,9-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-69-8 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-3-chloro-6,7,8,9-tetrahydro-2-methoxy-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-70-1 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-3-chloro-2-ethoxy-6,7,8,9-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-71-2 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-72-3 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866774-73-4 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-74-5 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866774-76-7 CAPLUS
CN 9H-Pyrido[2,3-b]azepine-9-carboxylic acid, 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-5,6,7,8-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-77-8 CAPLUS
CN 1H-Pyrido[3,4-b]azepine-1-carboxylic acid, 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-78-9 CAPLUS
CN 1H-Pyrido[4,3-b]azepine-1-carboxylic acid, 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-79-0 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6,7,8,9-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-80-3 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6,7,8,9-tetrahydro-2-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-81-4 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6,7,8,9-tetrahydro-3-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-82-5 CAPLUS
CN 5H-Pyrido[3,2-b]azepin-9-amine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(cyclopentylmethyl)-6,7,8,9-tetrahydro-2-methyl-N-(2-methyl-2H-tetrazol-5-yl)-3-(trifluoromethyl)- (CA INDEX NAME)



RN 866774-83-6 CAPLUS
CN 5H-Pyrido[3,2-b]azepin-9-amine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(cyclopropylmethyl)-6,7,8,9-tetrahydro-2-methyl-N-(2-methyl-2H-tetrazol-5-yl)-3-(trifluoromethyl)- (CA INDEX NAME)



RN 866774-84-7 CAPLUS
CN 5H-Pyrido[3,2-b]azepin-9-amine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-2-methyl-N-(2-methyl-2H-tetrazol-5-yl)-5-(3-pyridinylmethyl)-3-(trifluoromethyl)- (CA INDEX NAME)



RN 866774-85-8 CAPLUS
CN 5H-Pyrido[3,2-b]azepin-9-amine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-2-methyl-N-(2-methyl-2H-tetrazol-5-yl)-5-(4-pyridinylmethyl)-3-(trifluoromethyl)- (CA INDEX NAME)



RN 866774-86-9 CAPLUS
CN Benzoic acid, 3-[[9-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-5H-pyrido[3,2-b]azepin-5-yl]methyl]- (CA INDEX NAME)



RN 866774-87-0 CAPLUS
CN Benzoic acid, 4-[[9-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-5H-pyrido[3,2-b]azepin-5-yl]methyl]- (CA INDEX NAME)



RN 866774-88-1 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-pentanoic acid, 9-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-

yl)amino]-6,7,8,9-tetrahydro-β,β,2-trimethyl-3-(trifluoromethyl)-
(CA INDEX NAME)



RN 866774-89-2 CAPLUS
CN Cyclohexaneacetic acid, 4-[[9-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-5H-pyrido[3,2-b]azepin-5-yl]methyl]- (CA INDEX NAME)



RN 866774-90-5 CAPLUS
CN 5H-Pyrido[3,2-b]azepin-9-amine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-ethyl-6,7,8,9-tetrahydro-2-methyl-N-(2-methyl-2H-tetrazol-5-yl)-3-

(trifluoromethyl)- (CA INDEX NAME)



RN 866774-91-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[[9-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-5H-pyrido[3,2-b]azepin-5-yl]methyl]- (CA INDEX NAME)



RN 866774-92-7 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-ethanol, 9-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)- (CA INDEX NAME)



RN 866774-93-8 CAPLUS
CN 5H-Pyrido[3,2-b]azepin-9-amine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-2-methyl-N-(2-methyl-2H-tetrazol-5-yl)-5-(phenylmethyl)-3-(trifluoromethyl)- (CA INDEX NAME)



RN 866774-94-9 CAPLUS
CN 5H-Pyrido[3,2-b]azepin-9-amine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-2-methyl-N-(2-methyl-2H-tetrazol-5-yl)-5-(2-thiazolylmethyl)-3-(trifluoromethyl)- (CA INDEX NAME)



RN 866774-95-0 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-, tetrahydro-3-furanyl ester (CA INDEX NAME)



RN 866774-96-1 CAPLUS
CN Carbamic acid, [[3,5-bis(trifluoromethyl)phenyl]methyl][6,7,8,9-tetrahydro-2-methyl-5-(4-pyridinylmethyl)-3-(trifluoromethyl)-5H-pyrido[3,2-b]azepin-

9-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 866774-97-2 CAPLUS
CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[6,7,8,9-tetrahydro-2-methyl-5-(4-pyridinylmethyl)-3-(trifluoromethyl)-5H-pyrido[3,2-b]azepin-9-yl]- (CA INDEX NAME)



IT 1038588-70-3
RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of heterocyclic azepine derivs. as inhibitors of cholesterol ester transfer protein)

RN 1038588-70-3 CAPLUS

CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)



IT 866775-02-2P 866775-25-9P 866775-26-0P
866775-27-1P 866775-28-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic azepine derivs. as inhibitors of cholesterol ester transfer protein)

RN 866775-02-2 CAPLUS

CN 1H-Thieno[3,4-b]azepine-1-carboxylic acid, 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)



RN 866775-25-9 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866775-26-0 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[[[3,5-bis(trifluoromethyl)phenyl]methyl]cyanoamino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 866775-27-1 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-2H-tetrazol-5-ylamino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 866775-28-2 CAPLUS
CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid, 9-[[[3,5-bis(trifluoromethyl)phenyl]methyl]cyanoamino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:2730 CAPLUS
DOCUMENT NUMBER: 140:71043
TITLE: Combination treatment for depression and anxiety by NK1 and NK3 antagonists
INVENTOR(S): Sobolov-Jaynes, Susan Beth; Lowe, John Adams, III; McLean, Stafford
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004000355	A1	20031231	WO 2003-IB2516		20030610
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20040006135	A1	20040108	US 2003-386582		20030312
CA 2488311	A1	20031231	CA 2003-2488311		20030610
AU 2003239280	A1	20040106	AU 2003-239280		20030610
EP 1517708	A1	20050330	EP 2003-732858		20030610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003011898	A	20050412	BR 2003-11898		20030610
JP 2005533080	T	20051104	JP 2004-515136		20030610
MX 2005000260	A	20050411	MX 2005-260		20050103
PRIORITY APPLN. INFO.:			US 2002-389975P	P	20020619
			WO 2003-IB2516	W	20030610

OTHER SOURCE(S): MARPAT 140:71043
AB The invention discloses a method for treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK1 receptor antagonist (e. g., a substance P receptor antagonist) in combination with an NK3 antagonist agent. It also relates to pharmaceutical compns. containing a pharmaceutically acceptable carrier, a CNS-penetrant NK1 receptor antagonist and an NK3 antagonist.
IT 640277-50-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NK1 and NK3 antagonist combination treatment for depression and anxiety)
RN 640277-50-5 CAPLUS
CN Ethanone, 1-[(2R)-2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-piperazinyl]-2-[[6-(phenylmethyl)-6-azabicyclo[3.2.2]non-3-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT:	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:340180 CAPLUS
DOCUMENT NUMBER: 137:78847
TITLE: Rearrangement of a Mesylate Tropane Intermediate in Nucleophilic Substitution Reactions. Synthesis of Aza-Bicyclo[3.2.1]octane and Aza-Bicyclo[3.2.2]nonane Ethers,Imides, and Amines
AUTHOR(S): Ogier, Lionel; Turpin, Frederic; Baldwin, Ronald M.; Riche, Francoise; Law, Ho; Innis, Robert B.; Tamagnan, Gilles
CORPORATE SOURCE: Department of Psychiatry, Yale University and VA CT HCS, West Haven, CT, USA
SOURCE: Journal of Organic Chemistry (2002), 67(11), 3637-3642
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:78847
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Nonracemic mesyloxymethyltropane I undergoes nucleophilic substitution reactions with alcoholates, amines, and imides to give bicyclononanes II (R = H, Me; R1 = MeO, H2C:CHCH2O, 3,4-methylenedioxyphenoxy, N-phthalimidinyl, H2N, PhCH2NH) and substituted methyltropanes III (R2 = N-phthalimidinyl, H2N, PhCH2NH). Alcoholates give II as the sole products; amines and imides give mixts. of II and III. The reactivity of I is explained by intramol. neighboring group assistance to give the azetidinium mesylate IV; the regioselectivity of ring opening reactions of IV is determined by the hardness of the nucleophile. Other tropanes are also prepared
IT 440370-64-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nonracemic azabicyclo[3.2.2]nonanes and methyltropanes by stereoselective nucleophilic substitution reactions of a tropane mesylate with alcoholates, amines, and imides)
RN 440370-64-9 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[(1R,2S,5S,8S)-6-methyl-8-(4-methylphenyl)-6-azabicyclo[3.2.2]non-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 440370-65-0P 440370-66-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of nonracemic azabicyclo[3.2.2]nonanes and methyltropanes by stereoselective nucleophilic substitution reactions of a tropane mesylate with alcoholates, amines, and imides)
RN 440370-65-0 CAPLUS
CN 6-Azabicyclo[3.2.2]nonan-2-amine, 6-methyl-8-(4-methylphenyl)-, (1R,2S,5S,8S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 440370-66-1 CAPLUS
CN 6-Azabicyclo[3.2.2]nonan-2-amine, 6-methyl-8-(4-methylphenyl)-N-(phenylmethyl)-, (1R,2S,5S,8S)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:670114 CAPLUS
DOCUMENT NUMBER: 131:286538
TITLE: Preparation of 1,4-diacyl piperazines and analogs as neurokinin antagonists
INVENTOR(S): Blythin, David J.; Chen, Xiao; Friary, Richard J.; Mccormick, Kevin D.; Piwinski, John J.; Shih, Neng-yang; Shue, Ho-jane
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S., 85 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5968929	A	19991019	US 1997-958896	19971028
US 6051575	A	20000418	US 1999-313150	19990517

PRIORITY APPLN. INFO.: US 1996-29813P P 19961030
US 1997-958896 A3 19971028
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 131:286538
GI



AB Title compds. [I;R1 = C(:X)(CHRc')lA1; A1 = (un)substituted Ph, -naphthyl, -heteroaryl, etc.; R2 = (CH2)uA2; A2 = (un)substituted Ph, -naphthyl; R3 = [C(:X)]m(CHRc)yR; R = e.g., (di)azabicycloalkylamino having ring-N substituent G; G = H, alkyl, acyl, arylmethyl, etc.; Rc = H, alkyl, (CH2)1-4R4; R4 = ORa, NRaRb, CO2Ra, imidazolyl, etc.; Ra,Rb = H, alkyl, Ph, etc.; Rc' = H, (CH2)nORa; X = O, H2, NH, etc.; Z = (CH2)0-2; u,n,l = 0-2; m = 1 and y = 1-3; m = 2 and y = 0] were prepared Thus, (R)-1-bromoacetyl-2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)piperazine was aminated by 1,1-dimethylethyl 5-amino-2-azabicyclo[2.2]heptane-2-carboxylate (preparation each given) to give title compound II (R2 = 3,4-dichlorophenyl). Data for biol. activity of I were given.
IT 640277-50-5 1099570-38-3 1099570-39-4
1099570-40-7
RL: PRPH (Prophetic)
(Preparation of 1,4-diacyl piperazines and analogs as neurokinin antagonists)
RN 640277-50-5 CAPLUS

CN Ethanone, 1-[(2R)-2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-piperazinyl]-2-[[6-(phenylmethyl)-6-azabicyclo[3.2.2]non-3-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1099570-38-3 CAPLUS
CN 6-Azabicyclo[3.2.2]nonane-6-carboxylic acid, 3-amino-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1099570-39-4 CAPLUS
CN 6-Azabicyclo[3.2.2]nonane-6-carboxylic acid, 3-[[2-[2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-piperazinyl]-2-oxoethyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1099570-40-7 CAPLUS
CN Ethanone, 2-(6-azabicyclo[3.2.2]non-3-ylamino)-1-[2-(3,4-dichlorophenyl)-1-piperazinyl]- (CA INDEX NAME)



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	29	THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1993:551630 CAPLUS
DOCUMENT NUMBER: 119:151630
ORIGINAL REFERENCE NO.: 119:26901a,26904a
TITLE: Substituted benzamides with conformationally restricted side chains. 3. Azabicyclo[x.y.0] derivatives as gastric prokinetic agents
AUTHOR(S): Hadley, M. S.; King, F. D.; McRitchie, B.; Smith, D. M.; Turner, D. H.
CORPORATE SOURCE: SmithKline Beecham Pharm., Pinnacles/Harlow/Essex, CM19 5AD, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (1992), 2(9), 1147-52
CODEN: BMCLE8; ISSN: 0960-894X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The effect of alteration of ring size, introduction of alternative substituents and insertion of an exocyclic methylene group on the gastric prokinetic and dopamine antagonist activity of azabicyclic benzamides related to the serotonin 5-HT4 agonist, BRL 20627 is described.
IT 149978-20-1 149978-21-2 149978-22-3
RL: BIOL (Biological study)
(dpaminergic-antagonist and stomach-stimulating activity of, structure in relation to)
RN 149978-20-1 CAPLUS
CN Benzamide, 4-amino-5-chloro-N-(decahydropyrido[1,2-a]azepin-9-yl)-2-methoxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 149978-21-2 CAPLUS
CN Benzamide, 4-amino-5-chloro-N-(decahydropyrido[1,2-a]azepin-9-yl)-2-methoxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 149978-22-3 CAPLUS
CN Benzamide, 4-amino-5-chloro-N-(decahydropyrido[1,2-a]azepin-8-yl)-2-methoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L18 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1987:407086 CAPLUS
DOCUMENT NUMBER: 107:7086
ORIGINAL REFERENCE NO.: 107:1307a,1310a
TITLE: Azabicylcoalkanes procedure for their preparation, and their use as pharmaceuticals
INVENTOR(S): King, Francis David; Joiner, Karen Anne
PATENT ASSIGNEE(S): Beecham Group PLC, UK
SOURCE: Eur. Pat. Appl., 36 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 214772	A1	19870318	EP 1986-306221	19860812
R: BE, CH, DE, FR, GB, IT, LI, NL				
US 4798829	A	19890117	US 1986-896664	19860814
JP 62059278	A	19870314	JP 1986-190676	19860815

PRIORITY APPLN. INFO.: GB 1985-20616 A 19850816
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 107:7086
GI



I



Q



II



III

AB Azabicycloalkanes I [n = 1-3; m, p = 1, 2; m + n + p ≥ 4; X = NH, O; Ar = (un)substituted Ph, Q [R8, R9 = H, substituents, Z = CH2, O, S, (un) substituted NH, Y = CH, N; Z = CH, N, Y = (un)substituted NH, CH2]; R1, R2, R3 = H, alkyl, Ph, phenylalkyl, Ph(un)substituted by alkyl, alkoxy, halo], having gastric motility enhancing, and/or antiemetic, and/or 5-HT receptor antagonist activity, were prepared by reaction of ArG (G = COQ1; Q1 = leaving group) with II (L = NH2 or OH or a reactive derivative thereof). Oximation of 1-azabicyclo[3.2.2]nonan-4-one gave 75% the oxime-HCl, reduction of which with Na in amyl alc. gave 68% 4-amino-1-azabicyclo[3.2.2]nonane. Acylation with 3,5-Cl2C6H3COCl in CH2Cl2 gave 63% (±)-III. The ED50 of (±)-III to reduce the 5-HT

evoked response in rats was 0.008 mg/kg i.v. (antagonism of the van Bezold-Jarisch reflex from .apprx.6 μg/kg 5-HT).

IT 108551-28-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and conversion to free base)
RN 108551-28-6 CAPLUS
CN 1-Azabicyclo[3.2.2]nonan-4-amine, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

IT 108551-29-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and saponification of)
RN 108551-29-7 CAPLUS
CN Benzamide, 4-(acetylamino)-N-1-azabicyclo[3.2.2]non-4-yl-5-chloro-2-methoxy- (CA INDEX NAME)



IT 108551-27-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and N-aroylation of)
RN 108551-27-5 CAPLUS
CN 1-Azabicyclo[3.2.2]nonan-4-amine (CA INDEX NAME)



IT 108551-32-2P 108551-33-3P 108551-34-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as 5-HT receptor antagonist)
RN 108551-32-2 CAPLUS
CN Benzamide, 4-amino-N-1-azabicyclo[3.2.2]non-4-yl-5-chloro-2-methoxy- (CA INDEX NAME)



RN 108551-33-3 CAPLUS
CN Benzamide, N-1-azabicyclo[3.2.2]non-4-yl-3,5-dichloro- (CA INDEX NAME)



RN 108551-34-4 CAPLUS

CN 1H-Indazole-3-carboxamide, N-1-azabicyclo[3.2.2]non-4-yl-1-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L17 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN
RN 301335-12-6 REGISTRY
ED Entered STN: 06 Nov 2000
CN Benzamide, N-[(1S,3R,5R)-6-methyl-6-azabicyclo[3.2.2]non-3-yl]- (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H22 N2 O
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L17 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1027400-70-9 REGISTRY
ED Entered STN: 11 Jun 2008
CN 1-Azabicyclo[3.2.2]nonan-4-amine, 2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-, (2R,4R)- (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H34 N2 O
SR Other Sources
Database: ChemSpider (ChemZoo, Inc.)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L17 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1026691-71-3 REGISTRY
ED Entered STN: 09 Jun 2008
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH
MF C17 H26 N4 O2
SR Other Sources
Database: ChemSpider (ChemZoo, Inc.)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L17 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1026582-64-8 REGISTRY
ED Entered STN: 08 Jun 2008
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH
MF C20 H30 N2 O2
SR Other Sources
Database: ChemSpider (ChemZoo, Inc.)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT